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Abstract. The ability to interrogate thousands of proteins found in complex biological samples using proteomic technologies
has brought the hope of discovering novel disease-specific biomarkers. While most proteomic technologies used to discover
diagnostic biomarkers are quite sophisticated, “proteomic pattern analysis” has emerged as a simple, yet potentially revolutionary,
method for the early diagnosis of diseases. Utilizing this technology, hundreds of clinical samples can be analyzed per day and
several preliminary studies suggest proteomic pattern analysis has the potential to be a novel, highly sensitive diagnostic tool for
the early detection of cancer.
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1. Introduction
While having a tremendous impact on a variety of
biological research areas, a major focus of proteomics
is on the detection and identification of diagnostic
biomarkers [10]. In proteomics, a biomarker is gen-
erally defined as an identified protein that is unique to
a particular disease state. Experimentally, biomarker-
discovery using proteomics strives to scrutinize clini-
cal samples from healthy and afflicted individuals in a
high throughput manner, allowing for the relative abun-
dance of thousands of proteins from the two histopatho-
logically distinct samples to be ascertained. Samples
from healthy and diseased patients, for example, can be
resolved and visualized on separate two-dimensional
polyacrylamide gels. Protein spots that appear to be dif-
ferentially abundant by staining techniques can be ex-
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cised from the gel, digested, and identified using mass
spectrometry (MS) [13]. The hope is that the identified
protein(s) will indicate the pathological condition and
therefore a diagnostic marker or therapeutic target for
the disease of interest.
Despite the considerable intellectual and financial
resources invested over the past decade in the use of
conventional proteomic technologies for translational
research, success in the discovery of novel diagnostic
biomarkers has been remarkably poor. Reasons for
the lack of success can be divided into two factors;
technology-based and physiology-based. Technologi-
cally, the observed proteins are typically of high abun-
dance and therefore valuable biomarkers that are ex-
pressed at low abundances are not routinely detected
using current technology [23]. Comparison of just two
samples from healthy and diseased patients using con-
ventional proteomic technology is incredibly laborious
and may not provide meaningful data. Furthermore, the
identification of reliable and clinically useful biomark-
ers may require the comparison of thousands of sam-
ples. Physiologically, a useful biomarker would be ac-
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Fig. 1. A pictorial view of some of the various proteomic-based solutions used in the discovery of biomarkers.
cessible through an easily obtainable clinical sample
such as serum, plasma, or urine. The natural variability
of biofluids obtained from different patients makes the
identification of a unique biomarker, within a sample
with a constantly changing background matrix, quite
challenging. In addition, a single, definitive biomarker
for a particular physiological condition, such as human
chorionic gonadotropin for pregnancy, may be quite
rare [5]. Indeed, clinically accepted tests for such dis-
eases as ovarian and prostate cancer through the de-
tection of the biomarkers cancer-antigen (CA) 125 [9]
and prostate specific antigen (PSA) [8], respectively,
possess rather low positive predictive values (PPV).
Presently there exists several different proteomic
based approaches that can be used to attempt to dis-
cover novel biomarkers. A few of these approaches
are illustrated in Fig. 1. While mass spectrometry
(MS) based approaches seem to dominate the search
for biomarkers, there is a very active research program
into the use of protein arrays that measure the abun-
dance, or extent of modification of particular proteins
through their interaction with specific affinity reagents
such as antibodies or aptamers. Many of the MS-
based approaches focus on the identification of differ-
entially abundant proteins as indicated by their sep-
aration by two-dimensional polyacrylamide gel elec-
trophoresis (2D-PAGE) followed by visualization by
staining or by solution based differential analysis such
as isotope-coded affinity tags (ICAT) in which proteins
from different sources are labeled with isotopic vari-
ants of a cysteine-specific tag [25]. A novel approach
to identify differences in protein abundances between
cell types has been pioneered by Richard Caprioli. This
approach, termed MS imaging, involves the direct anal-
ysis of tissue samples using matrix assisted laser des-
orption (MALDI) MS. In a recent application of this
technique, MALDI-MS spectra were obtained directly
from 1-mm regions of single frozen tissue of sections
from 79 lung tumors and 14 normal lung tissues [24].
A class-prediction model was constructed using the
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Fig. 2. Pie chart representing the relative contribution of proteins within plasma. Twenty two proteins constitute approximately 99% of the
protein content of plasma.
proteomic patterns of a training cohort of 42 lung tu-
mours and eight normal lung samples. This model was
able to perfectly classify lung cancer histologies, dis-
tinguish primary tumours from metastases to the lung
from other sites, and classify nodal involvement with
85% accuracy in the training cohort and nearly per-
fectly classified samples in the independent blinded test
cohort. These results suggest that proteomic patterns
obtained directly from small amounts of fresh frozen
lung-tumour tissue can accurately classify and predict
histological groups as well as nodal involvement and
survival in resected non-small-cell lung cancer. One
method that has attracted considerable attention over
the past couple of years, however, has been surface
enhanced laser desorption and ionization time-of-flight
(SELDI-TOF) MS [12,19], which has contributed to
the development of a potentially revolutionary method
for diagnosing diseases through proteomic patterns, as
describe below.
2. Serum as a source of diagnostic information
Serum is arguably the most important source of di-
agnostic information to describe the histopathological
state of a patient. While serum potentially contains a
plethora of diagnostic information, surprisingly little
has been known about it protein content until very re-
cently. Since serum has a very high protein concentra-
tion (i.e. 50–80 mg/mL), this would make one think that
serum is an ideal sample for proteomic analysis. Un-
fortunately, 99% of this protein concentration is made
up by only 22 proteins, with albumin itself making up
approximately 50% of serum’s protein content (Fig. 2).
The dynamic range of protein concentration has been
estimated at approximately 9–10 orders of magnitude,
making the characterization of the proteins within the
lower 1% of protein abundance an analytically chal-
lenging endeavor.
Fortunately, as proteomic know-how and technolo-
gies have increased in their capabilities over the re-
cent years, there are several studies that provide a
glimpse into the protein makeup of this low abundance
fraction of serum. One of the original studies used
immunoglobulin (Ig)-depleted serum, which was di-
gested with trypsin and fractionated using strong cation
exchange chromatography (SCX) [2]. Each of the
SCX fractions were characterized using microcapillary
reversed-phase liquid chromatographycoupled directly
on-line with tandem MS (µLC-MS/MS). This study
resulted in the identification of 490 unique proteins,
the largest number of proteins identified in serum to
date. While many of the highest abundant proteins,
such as albumin, complement factors, etc. were identi-
fied, so to were several proteins, such as prostate spe-
cific antigen and interleukin-12, which are known to be
present in very low concentration within serum. An-
other recently published study separated a tryptic di-
gest of whole serum using preparative isoelectric fo-
cusing (IEF) prior to µLC-MS/MS peptide identifica-
tion. In this study more than 300 serum proteins were
identified [26]. Surveying both studies show that pro-
teins from every biological and functional class were
represented within serum, as well as proteins from ev-
ery cellular locale. Taken together, these studies show
that serum is made up of a wealth of proteins that are
secreted or shed by cells that are either healthy or tu-
morigenic or dying. This characteristic of serum does
make it an rich source of finding potential biomarkers
for histopathological conditions.
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3. Proteomic pattern technology
Unfortunately, the inherent complexity of serum rep-
resents an overwhelming challenge to conventional pro-
teomic approaches in which peptide abundances are
compared and species of interest are subsequently iden-
tified. The comparison of just two serum samples using
conventional proteomics technology will undoubtedly
show many differences in protein abundances,however,
determining the relevance of these changes to a specific
disease state is very difficult. In addition, just compar-
ing two serum samples in this manner would require
days (if not weeks) of sample processing, data acquisi-
tion, and data processing time: much too slow and la-
borious for what needs to be done on a high-throughput
basis. A revolutionary proteomic technology has re-
cently been developed that does not rely on identifica-
tion of any of the components within serum, rather it
relies on the overall mass spectral pattern generated by
a clinical sample of interest. The analytical methodol-
ogy of the proteomic pattern approach is illustrated in
Fig. 3. Proteomic patterns are acquired using surface
enhanced laser desorption/ionization (SELDI) time-of-
flight (TOF) MS [12] as shown in Fig. 4. In SELDI-
TOF MS raw biofluids are applied to a chromatographic
surface of a protein chip that selectively retains compo-
nents within the sample via adsorption, partition, elec-
trostatic interaction, or affinity chromatography. One
of the unique benefits, and what distinguishes SELDI-
TOF MS, is that raw biofluids, such as urine, serum,
and plasma, can be directly applied to the protein chip
array surface. After a series of binding and washing
steps, an energy-absorbing matrix is applied to each
sample and a nitrogen laser is used to desorb and ion-
ize bound species enabling their mass-to-charge (m/z)
ratios to be measured by TOF MS. The result is a mass
spectrum of the retained species on the protein chip
array surface. The overall simplicity of the technology
has contributed to the popularity of SELDI TOF MS to
the biological community, as minimal expertise in the
operation of MS instrumentation is required to generate
mass spectral data.
3.1. Application of proteomic patterns for disease
diagnosis
The potential of proteomic pattern analysis was first
demonstrated in the diagnosis of ovarian cancer [19].
While ovarian cancer is not the most common cause of
cancer-related deaths in women, 80% of women with
common epithelial cancer are not diagnosed until the
diseased is in advanced stages where the five-year sur-
vival rate is only 15–20% [18]. If diagnosed at stage 1,
the five-year survival rate rises dramatically to approx-
imately 95% with surgical intervention. In this original
study, the proteomic patterns of serum samples from
several controls and ovarian cancer patients were ac-
quired and a bioinformatic analysis,which combines el-
ements of a genetic algorithm with cluster analysis [11,
15,16], was applied to the data to decipher diagnostic
“patterns” within the profiles.
The analysis is divided into a pattern discovery and
a pattern-matching phase. In the pattern discovery
phase a set of randomly selected mass spectra of serum
from healthy and ovarian cancer-affected individuals
(i.e. the “training set”) is analyzed to identify a sub-
set of m/z values and their amplitudes whose distinct
presence distinguishes the normal serum spectra from
the histopathological serum spectra. The bioinformatic
searching process begins with hundreds of arbitrary
choices of small sets (i.e. five to 20) of the m/z values of
the mass spectra. The diagnostic pattern is composed
of the combined y-axis amplitudes of the candidate set
of the key m/z values. The pattern formed by the rela-
tive amplitudes of the chosen m/z values is tested for its
ability to distinguish the serum mass spectra acquired
from the healthy and cancer-affected individuals. With
the aim of identifying the pattern that provides the opti-
mal segregation, the m/z values within the most fit sets
of features for distinguishing the training set spectra
are reshuffled to form new feature sets and the resul-
tant defined amplitude values are rated iteratively until
the feature set that fully discriminates the preliminary
sample spectra is revealed.
Once the most fit key m/z values are selected, the
diagnostic model, identified in the pattern discovery
phase, is tested using masked spectra (i.e. the “testing
set”). In this so-called pattern-matching phase only
the key m/z values and intensities in the feature set
identified in the pattern discovery phase are used to
classify the unknown samples as being from healthy or
cancer-affected individuals. The diagnostic feature set
defined in training was able to correctly diagnose the
samples as being acquired from either control patients
or those suffering from ovarian cancer with a sensitivity
of 100% and a specificity of 95%, yielding an overall
PPV of 94% [19]. The success in correctly deciphering
stage I ovarian cancer suggested that proteomic patterns
generated from biofluids may provide a useful indicator
of the early onset of a particular disease state.
L.-R. Yu et al. / Diagnostic proteomics: Serum proteomic patterns for the detection of early stage cancers 213
Fig. 3. Disease diagnostics using proteomic patterns. The serum sample is applied to a chromatographic surface that is arrayed onto a protein
chip. After several washing steps, an energy-absorbing molecule is applied to the sample, and the mass spectrum of the species retained on the
surface of the chip is acquired using laser desorption ionization (LDI) time-of-flight (TOF) mass spectrometry. The pattern of peaks within the
spectrum is analyzed using sophisticated bioinformatic software to diagnose the source of the serum sample.
Fig. 4. Schematic diagram of the SELDI PBS-II mass spectrometer. After sample preparation the ProteinChip arrays are analyzed by a laser
desorption ionization (LDI) time-of-flight mass spectrometer (TOF MS). The TOF MS measures the mass-to-charge (m/z) ratios weights of the
various proteins that are retained on the array.
3.2. Technologic comparison of three SELDI-TOF
reports on prostate cancer
While proteomic pattern analysis represents a poten-
tially valuable method to diagnose early stage cancer,
one major criticism of the technology is that the iden-
tity of the proteins or peptides giving rise to the key di-
agnostic features is not known [7]. As shown in Fig. 4,
these features typically manifest as low intensity sig-
nals and developing methods to extract these potential
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biomarkers from a complex milieu such as serum is not
trivial. At this stage in the development of proteomic
pattern analysis it is debatable as to whether it is worth
the effort to identify these features as they may provide
little aid in developing an alternative diagnostic plat-
form. Indeed, many of the diagnostic features are of
low m/z (i.e. <10 kDa) and it is therefore likely that
they are fragments generated from larger proteins that
are proteolyzed in the tumor/host microenvironment. A
recent study conducted in our laboratory to characterize
components within the low molecular weight fraction
of the serum proteome has shown that many of the iden-
tified peptides that pass through a 30 kDa molecular
cut-off membrane, originate from proteins with intact
molecular masses much greater than the cut-off limit
of the membrane [22]. It would be extremely challeng-
ing to generate an affinity reagent with specificity to a
peptide fragment without considerable cross reactivity
to its parent protein. Indeed, identification of a specific
biomarker does not guarantee that this knowledge will
provide any mechanistic or therapeutic insights into a
particular cancer. A notable example of this situation
is PSA. PSA is used to indicate the possible presence
of a prostatic tumor, yet its role in cancer develop-
ment remains unclear. Conversely, the identification
of these diagnostic features is of considerable interest
to the medical community and will likely be a major
component of this technology in the near future.
Another major criticism is that studies using the same
technology to develop a diagnostic for the same can-
cer, different peaks are recognized by the algorithms as
crucial in distinguishing serum from healthy and dis-
eased individuals. For example, three different prostate
cancer detection studies reported 83% sensitivity at
97% specificity [1], 95% sensitivity at 78–83% speci-
ficity [20], and 97–100% sensitivity at 97–100% speci-
ficity [21]. The data from each study was roughly com-
parable and clearly superior to the specificity obtained
by prostate-specific antigen (PSA) testing ( 25%) while
having similar sensitivities. It is surprising, however,
that the two groups in three studies obtained these re-
sults using different methodologies and distinguishing
peaks. Two of the groups used [1,21] an IMAC-Cu
metal-binding chip for serum adsorption while the third
group used a hydrophobic C-16 chip [20]. While one
group using the IMAC chips found that [1] nine peaks
at m/z ratios of 4475, 5074, 5382, 7024, 7820, 8141,
9149, 9507, and 9656 allowed serum from healthy and
prostate cancer-afflicted individuals to be segregated,
the study using the C-16 chips [20] selected different
peaks at m/z ratios of 2092, 2367, 2582, 3080, 4819,
5439, and 18220. The other group that used IMAC
chips [21] identified 12 major peaks at m/z ratios of
9656, 9720, 6542, 6797, 6949, 7024, 8067, 8356, 3963,
4080, 7885, and 6991 for differentiating noncancer
from cancer and 9 peaks at m/z ratios of 7820, 4580,
7844, 4071, 7054, 5298, 3486, 6099, and 8943 for
differentiating healthy individuals from patients with
benign prostatic hyperplasia. There was no common-
ality between the peaks selected when comparing the
results obtained using the IMAC and C-16 chips, how-
ever, more surprisingly, there were only two peaks in
common (i.e. m/z 7024 and 9656) when the studies per-
formed using the IMAC chips were compared; even
though these studies were performed using the same
protein chips and mass spectrometer. One (albeit very
unlikely) explanation to this discrepancy is fundamen-
tal to the analytical procedure while another is funda-
mental to the algorithm used to identify these key dis-
criminatory features. As far as the analytical proce-
dure, the spectral patterns acquired are very sensitive
to experimental details such as how the serum is col-
lected and stored. Any slight deviations from a stan-
dard protocol could result in changes in the proteomic
pattern provided by a particular serum sample. As far
as the algorithm is concerned, since serum is a very
complex mixture of proteins and peptides there may be
thousands of potential distinguishing peaks in serum.
The chances that two different groups would find the
same discriminating peaks using different instruments
and computer algorithms would be extremely low.
3.3. Instrumental improvements
Several laboratories have subsequently shown the
ability of serum proteomic patterns to diagnosis
breast [17] and prostate [4,20,21] cancers with sensitiv-
ities and specificities greater than 90%. While this di-
agnostic success rate is quite high, to function as an ef-
fective screening tool, a diagnostic assay screening for a
low-prevalence disease such as ovarian cancer requires
a specificity of at least 99.6% [14]. The need for such
a high level of specificity for a clinical screening test
can be rationalized if one considers that a false positive
rate of even two percent for a low prevalence disease
such as ovarian cancer would overwhelm the present
medical system with unnecessary biopsies. Therefore,
while proteomic pattern analysis in its present state rep-
resents a useful tool to confirm a diagnosis of cancer,
its use as a screening tool for high-risk populations is
still limited.
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All of the above mentioned studies have been per-
formed using a PBS-II, which is a simple TOF-MS that
is designed to provide for a broad m/z detection range at
the expense of resolution. A recent study compared the
results of analyzing 248 serum samples from healthy
and ovarian-cancer afflicted patients on a PBS-II and
a hybrid quadrupole TOF (QqTOF) MS fitted with a
SELDI ion source [6]. The resolution obtainable with
the QqTOF MS is 60-fold higher than that obtainable
with the PBS-II TOF MS, however, the spectra acquired
on the different instruments are qualitatively similar.
Twenty-eight serum samples from unaffected women
and 49 women with ovarian cancer were used for the
training set in the bioinformatic analysis described
above. A total of 108 diagnostic models were generated
using a variety of different combinations of bioinfor-
matic heuristic parameters. None of these parameters
had any effect on the raw MS data, they were simply
related to the bioinformatic process of generating diag-
nostic models from the raw data. These parameters in-
cluded such things as the similarity space of likeness for
cluster classification, the feature set size of random m/z
values whose combined intensities comprise each pat-
tern, and the learning rate in training of the genetic algo-
rithm. All of the models were derived and queried with
the same set of proteomic pattern spectra. The models
derived from the training sets acquired on the different
MS platforms were tested using blinded serum sam-
ple mass spectra obtained from 31 unaffected women
and 63 women with ovarian cancer. They were further
validated using blinded serum sample spectra obtained
from 37 unaffected women and 40 women with ovarian
cancer. The diagnostic models generated from mass
spectra acquired using the higher resolution Qq-TOF
MS were statistically superior not only in testing but
also in validation to those acquired on the PBS-II.
Quite importantly, four models were found that were
both 100% sensitive and specific in their ability to cor-
rectly discriminate between serum samples originating
from unaffected women and those suffering from ovar-
ian cancer. Each of these models was generated with
data acquired on the Qq-TOF MS, as no models with
both 100% sensitivity and specificity could be found
using the PBS-II data. No false positive or false neg-
ative classifications occurred using these models, giv-
ing each of these models a PPV of 100% using the pa-
tient cohort employed in this study. Each of these four
models were able to correctly classify 22/22 women
with stage I ovarian cancer, 81/81 women with stage
II, III and IV ovarian cancer, and 68/68 benign disease
controls.
As opposed to the three prostate studies mentioned
previously that gave differing key m/z features within
the most diagnostic models, the key m/z features that
comprise the four diagnostic models obtained using the
QqTOF-MS data that had 100% PPV for ovarian can-
cer revealed certain consistent features. Though the
proteomic patterns generated from both healthy and
cancer patients using the Qq-TOF MS are quite similar
(Fig. 5), peaks at m/z values 7060.121 and 8605.678
are more pronounced in a selection of the serum sam-
ples obtained from ovarian cancer patients as compared
to unaffected individuals. This represented the first
demonstration of consistency within diagnostic models
and showed that several diagnostic models with high
sensitivity and specificity can be obtained from a single
set of data.
4. Conclusions
It is often anticipated that mass spectrometry will be
used to identify the relevant biomarkers for a particu-
lar disease state and this information will be used to
generate some type of affinity reagent (i.e. antibody,
aptamer, etc.) that can be incorporated into an ELISA-
based platform to screen serum samples for the pres-
ence of the biomarker originally identified by MS. The
reasoning is that MS doesn’t offer the throughput and
reproducibility available using an ELISA-based sys-
tem. There may be some technical difficulties associ-
ated with quantitating relevant serum biomarkers iden-
tified by MS. A recent study examining the low molec-
ular weight proteome offers some clues to these dif-
ficulties [22]. In this study, serum was diluted five-
fold in buffer containing 20% acetonitrile to disrupt
non-covalent protein-protein interactions. The serum
sample was then filtered through a 30 kDa molecular
weight cutoff membrane. The low molecular weight
fraction that passed through the membrane was di-
gested with trypsin and the resulting peptides analyzed
by liquid chromatographycoupled directly on-line with
tandem MS so as to identify these peptides. Of the
more than 800 unique peptides that were identified in
this study, many were found to originate from proteins
whose molecular weight was substantially greater than
30 kDa. One of these proteins, von Willebrand’s fac-
tor has a molecular weight of 309 kDa. To confirm
the presence of peptides from large proteins, the low
molecular weight serum fraction was run on a SDS-
PAGE gel and several bands corresponding to molecu-
lar weights of less than 30 kDa were excised from the
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Fig. 5. Top: List of the key m/z values in four diagnostic models that allowed serum acquired from healthy patients to be discriminated from
serum acquired from ovarian cancer patients with 100% sensitivity and specificity. Bottom: Differential abundance of two key m/z features
selected in three of the four most diagnostic models differentiating serum acquired from unaffected and ovarian cancer-affected individuals.
gel. After performing and in-gel tryptic digestion, the
peptides were extracted from the gel and identified by
LC-MS/MS. Indeed several of these proteins that ran
with an apparent molecular weight during SDS-PAGE
less than 30 kDa, were identified as much larger pro-
teins. These results suggest that many of the biomark-
ers identified as diagnostic for a particular disease state
may be fragments from larger proteins. It would prove
challenging to develop an affinity reagent that was spe-
cific for a fragment of a protein and did not cross-react
with the intact protein itself. Probably the most im-
portant result to come from this serum characterization
study was the finding that their exists an ocean of po-
tential biomarkers within serum, as proteins from every
general functional class, including oncogene products,
were observed in this analysis.
One of the limitations of using individual cancer
biomarkers is their lack of sensitivity and specificity
when applied to large heterogeneous populations. It is
likely that the measurement of a panel of biomarkers
for a disease state can dramatically increase the over-
all diagnostic accuracy [3]. Biomarker pattern analysis
is an emerging technology aimed at overcoming this
limitation. While proteomic pattern analysis does not
measure a panel of identified biomarkers, it does mea-
sure a panel of signals whose combination of m/z val-
ues and relative amplitudes allows for the correct diag-
nosis. Focusing in on an individual peak, or subgroup
of peaks does not provide the sensitivity and specificity
attained from the combination of the diagnostic fea-
tures. This multiplexed measurement makes inherent
sense when one considers the systemic invasiveness of
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diseases such as cancer, in which the change of a sin-
gle species due to tumor formation would be highly
unlikely.
While disease diagnostics using proteomic patterns
has rapidly emerged as a potentially revolutionary tool
to detect and monitor disease progression or therapeu-
tic response, it represents a complete about face in pro-
teomic analysis. The major thrust in proteomics us-
ing MS-based technology over the past five years has
been to identify and characterize an increasing num-
ber of proteins from a particular clinical sample in
order to find a disease-specific biomarker. Diagnos-
ing histopathological conditions via a proteomic pat-
tern instead of assaying an identified disease-related
biomarker represents a new paradigm in the use of MS-
based tools for the discovery of diagnostic markers.
The diagnosis of diseases, such as cancer, using pro-
teomic patterns holds great promise. Since it is a rel-
atively new concept, however, much of the entire pro-
cess, including sample acquisition and processing, pat-
tern acquisition, and data analysis requires optimiza-
tion. The success of using this technology as a screen-
ing tool to detect early stage cancer, for example, will
require recognition and establishment of strict quality
controls so that samples being analyzed within differ-
ent laboratories are treated identically. While many
valid criticisms still abound, the high sensitivity and
specificity that has been shown in several studies us-
ing proteomic pattern as a diagnostic test cannot be
ignored.
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